Ranibizumab for Macular Edema following Central Retinal Vein Occlusion

To assess the efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion (CRVO).Prospective, randomized, sham injection-controlled, double-masked, multicenter clinical trial.A total of 392 patients with macular edema after CRVO.Eligible patients were randomized 1:1:1 to receive monthly intraocular injections of 0.3 or 0.5 mg of ranibizumab or sham...